Q1 Earnings Forecast for Neurogene Issued By HC Wainwright

Neurogene Inc. (NASDAQ:NGNE) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Neurogene in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst M. Kapoor expects that the company will earn ($0.85) per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.98) EPS and FY2025 earnings at ($3.68) EPS.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.05. The company had revenue of $0.93 million for the quarter.

Separately, William Blair restated an “outperform” rating on shares of Neurogene in a research note on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $59.80.

Neurogene Price Performance

NGNE opened at $15.33 on Thursday. The company has a 50 day simple moving average of $16.92 and a two-hundred day simple moving average of $28.96. The firm has a market cap of $227.73 million, a P/E ratio of -3.59 and a beta of 1.01. Neurogene has a 1-year low of $13.47 and a 1-year high of $74.49.

Institutional Investors Weigh In On Neurogene

Several large investors have recently made changes to their positions in NGNE. Samsara BioCapital LLC boosted its stake in Neurogene by 35.4% during the fourth quarter. Samsara BioCapital LLC now owns 1,717,127 shares of the company’s stock valued at $39,254,000 after buying an additional 449,337 shares during the last quarter. RTW Investments LP raised its holdings in shares of Neurogene by 18.9% during the 4th quarter. RTW Investments LP now owns 1,350,256 shares of the company’s stock worth $30,867,000 after acquiring an additional 215,000 shares in the last quarter. Redmile Group LLC boosted its position in shares of Neurogene by 36.9% during the 4th quarter. Redmile Group LLC now owns 1,319,763 shares of the company’s stock valued at $30,170,000 after acquiring an additional 355,416 shares during the last quarter. Casdin Capital LLC grew its holdings in shares of Neurogene by 146.9% in the fourth quarter. Casdin Capital LLC now owns 1,295,361 shares of the company’s stock valued at $29,612,000 after purchasing an additional 770,745 shares in the last quarter. Finally, FMR LLC increased its position in Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after purchasing an additional 659,515 shares during the last quarter. 52.37% of the stock is owned by institutional investors.

Insider Buying and Selling at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,501 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the sale, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. The trade was a 5.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.92% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.